Olema Pharmaceuticals appoints Jason O'Byrne as CFO, effective Aug 11, 2026

Olema Pharmaceuticals, Inc.

O'Byrne previously CFO at Vir Biotechnology (2024-2026) and Caribou Biosciences (2021-2024); joins Olema from Vir.
Compensation: $545,000 base salary, 45% target bonus, $250,000 sign-on bonus plus $100,000 at 1-year anniversary.
Granted option for 650,000 shares under 2022 Inducement Plan, vesting over 4 years (25% at 1-year, then monthly).
Company cites upcoming pivotal OPERA-01 data and first potential commercial launch; highlights palazestrant and OP-3136.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.